Apyx Medical Corp. (APYX) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook
November 11, 2021 4:05 PM ESTAdvanced Energy Sales increased 88% year-over-year in Q3
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its third quarter ended September 30, 2021 and updated its financial outlook for the full year ending December 31, 2021.
Third Quarter 2021 Financial Summary:
Total revenue of $11.8 million, up 70%... More